UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
News Opdivo gains European approval for Hodgkin lymphoma Latest approval for Opdivo good news, but won't make up for lung cancer setback
Views & Analysis NICE and NHS England unveil ‘fast-track’ and affordability s... NHS England will be able to control cost impact of NICE decisions more directly.
ESMO2016 Cancer Market Commentary: Keytruda’s triumph not the last wo... Despite Keytruda's overwhelming victory, it's not over yet in NSCLC
ESMO2016 Cancer market commentary: Roche’s Tecentriq muscles into NSC... Roche's PD-L1 drug has generated impressive data in second line lung cancer
News BMS and Nektar to pair Opdivo with natural killer cell drug BMS and Nektar's combination latest in frenzied immunotherapy field
News Gilead, MSD share data on once-weekly oral HIV treatment Gilead/MSD's once-weekly oral medicine for HIV has been shown to achieve high rates of viral suppression in phase 3, setting up regulatory filings.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
